NEW YORK, Sept. 6, 2013
/PRNewswire/ -- S&P Capital IQ announced today that it has
commenced Standard & Poor's Factual Stock Report coverage on
Epigenomics AG.
Epigenomics AG (OTC: EPGNY; FSE: ECX) is a molecular diagnostics
company focusing on developing and commercializing of in vitro
diagnostic (IVD) tests for the screening and diagnosis of cancer.
The company's products are based on a technology platform, which
relies on a fundamental biological phenomenon called DNA
methylation as a source for the discovery of highly informative and
disease-specific biomarkers which are at the core of every
diagnostic test it has developed so far.
Epigenomics develops and commercializes diagnostic tests in
colorectal cancer (CRC) and in lung cancer; both via direct
marketing and sales efforts of IVD kits and through non-exclusive
licensing partnerships for the biomarkers constituting the basis
for these products. The company directly addresses certain market
segments with its own products, while others are or will be served
by partners through the licenses granted to them.
The company's lead product is Epi proColon®, a
blood-based test for the early detection of CRC which relies on its
DNA methylation biomarker, Septin9. The majority of Epigenomics'
activities are focused on the introduction of Epi
proColon® as an IVD kit in the
United States, the world's largest commercial market for
molecular diagnostic products. In 2012, the company completed the
Premarket Approval (PMA) application and is expecting an approval
decision from the U.S. Food and Drug Administration (FDA) before
the end of 2013. Blood-based tests using the Septin9 biomarker are
available worldwide through the company's partners, including
Abbott Molecular Diagnostics, Inc., Quest Diagnostics, Inc., ARUP
Laboratories, Inc., Gamma Dynacare, and Companion Dx Reference Lab.
The product and diagnostic service offerings are performed on the
basis of licenses granted to these partners by Epigenomics.
In July 2013, Epigenomics
announced findings from a health economic study done at
Stanford University School of Medicine.
According to the study, Septin9 testing provided potential for
saving lives while being health economically beneficial as an
attractive screening alternative to established methods for a
population that would otherwise be non-compliant to CRC
screening.
On March 7, 2013, Epigenomics
announced that it signed a licensing agreement with BioChain for
Septin9 in China.
Standard & Poor's Factual Stock Report coverage on
Epigenomics AG will also be accessible on an ongoing basis to the
investment community by scores of buy-side institutions and
sell-side firms that utilize S&P Capital IQ research and
information platforms daily. Millions of self-directed investors
also have access to the report via their e-brokerage accounts.
Please visit http://www.epigenomics.com/de for additional
information.
About Standard & Poor's Factual Stock Reports
Currently profiling approximately 500 issuers, Standard &
Poor's Factual Stock Reports, produced by S&P Capital IQ,
increase market awareness of issuers in the investment community
with insightful commentary and key statistics and information.
Standard & Poor's Factual Stock Reports provide factual
research coverage about company fundamentals and business
prospects, thereby enabling information about covered companies to
reach a wide investor audience of Buy and Sell-side investors.
Updated weekly with the latest pricing, trading volume, and other
data, the reports include recent developments, a financial review,
key operating information, industry and peer comparisons,
institutional holdings analysis, Street Consensus and opinions,
performance charts, business summary, fundamental data, and news.
Because coverage of these reports is underwritten by the issuer,
S&P Capital IQ does not offer investment opinions concerning
the advisability of investing in these stocks.
Standard & Poor's Factual Stock Reports are produced
separately from any other analytic activity of S&P Capital IQ
or related organizations. S&P Capital IQ does not trade
on its own account.
About S&P Capital IQ
S&P Capital IQ, a part of McGraw Hill Financial, is a
leading provider of multi-asset class and real time data, research
and analytics to institutional investors, investment and commercial
banks, investment advisors and wealth managers, corporations and
universities around the world. Evaluated pricing is prepared by
Standard & Poor's Securities Evaluations, Inc., a part of
S&P Capital IQ and a registered investment adviser with the
U.S. Securities and Exchange Commission. In the United
States, research reports are prepared by Standard & Poor's
Investment Advisory Services LLC, a part of S&P Capital IQ and
a registered investment adviser with the U.S. Securities and
Exchange Commission. S&P Capital IQ provides a broad suite of
capabilities designed to help track performance, generate alpha,
and identify new trading and investment ideas, and perform risk
analysis and mitigation strategies. Through leading desktop
solutions such as the S&P Capital IQ, Global Credit Portal and
MarketScope Advisor desktops; enterprise solutions such as S&P
Capital IQ Valuations; and research offerings, including Leveraged
Commentary & Data, Global Markets Intelligence, and company and
funds research, S&P Capital IQ sharpens financial intelligence
into the wisdom today's investors need. For more information visit:
www.spcapitaliq.com.
Contacts
Epigenomics AG
Antje Zeise (Manager Investor
Relations)
phone: +49-30-24345-0
fax: +49-30-24345-555
ir@epigenomics.com
or
S&P Capital IQ
Customers
Richard Albanese, 212-438-3647
richard.albanese@spcapitaliq.com
or
Media Relations
Michael Privitera, 212-438-6679
michael.Privitera@spcapitaliq.com
SOURCE S&P Capital IQ